Epsilogen CEO, Tim Wilson, shares his company’s experience finding the right CDMO partner, willing to collaborate with a small biotech on developing and manufacturing a novel class of antibodies, IgE-based immunotherapies, designed to combat solid tumors, which account for 92% of all cancers.
You may also be interested in:
Mammalian
Difficult to Express Proteins
Cell Line Development
Clinical Supply Services
Read this article
View now
Latest briefing from the Knowledge Center
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Article
Partnering for Innovation: Lonza Supports a UK Biotech Developing an Entirely New Modality with...
Epsilogen CEO, Tim Wilson, shares his company’s experience finding the right CDMO partner, willing...
White paper
Transferring your cell line with confidence
This white paper explores flexible, data-driven strategies that help streamline biologics...
Article
Q&A: Getting it right first time - the importance of early expression vector design
In this interview, Lonza’s Dr. Peter O’Callaghan (Senior Director, Head of Expression System...
Technical/Service brief
GS Gene Expression System: reliability today, innovation for tomorrow
Emerging and small biotechs play a critical role in driving scientific innovation, often advancing...
Article
The Evolving Landscape of ADC Analytical Development
Lentivirus modeled above hand
White paper
Xcite®: an optimized transient transfection platform to accelerate your AAV program from gene to...
Unlock the full potential of your AAV program with Xcite®: a proven path from gene to GMP by being...
Lonza Bend Solid Form Services
Webinar (on-demand)
Amorphous Solid Dispersions (ASDs): Pre-clinical to Commercial Capabilities
Is your drug candidate struggling with solubility, slowing down its path to market?...
Capsule services
White paper
Unlock key insights of end-to-end regulatory CDMO solutions
Navigating the complex world of drug development and regulatory approval just got easier. Our recent...
Webinar (on-demand)
Lonza's integrated ADC offering: From concept to commercialization
As the Antibody-Drug Conjugate (ADC) market continues its robust expansion, the demand for...
Used as thumbnail for Powder to Particles podcast.
Webinar (on-demand)
Solving the inhalation puzzle: A CDMO's guide to dry powder development
Unlock the secrets to successful pulmonary and nasal drug delivery with our exclusive on-demand...
Mammalian Biologics Drug Substance Manufacture MC1
Webinar (on-demand)
Navigating the CMC regulatory landscape during protein medicinal product development and...
Explore the evolving regulatory landscape for protein-based therapeutics in this on-demand webinar....